retatrutide peptide injection site hi-res stock photography and images Retatrutide Injection: Package Insert /

Biosci Biotechnol Biochem

The compound is identified in the published clinical-research literature under the development designation LY3437943 and is sometimes called a "triple-hormone-receptor agonist" in the field

Weeks 12: 2 mg once weekly Weeks 34: 4 mg once weekly Weeks 58: 8 mg once weekly Week 9+: 12 mg once weekly Efficacy and safety: The reason for the slow and gradual dosing protocol The Phase 2 clinical trial of retatrutide demonstrated that participants receiving the highest dose (12 mg) achieved up to 24% weight reduction after 48 weeks

rotate: Lamiophlomis rotate SM: Shanzhiside methylester MAPK: p38 mitogen-activated protein kinase DPN: Diabetic peripheral neuropathy MCU: Mitochondrial calcium uniporter UCP3: Uncoupling protein 3 DRP1: Dynamin-related protein 1 STZ: Streptozotocin ERK: Extracellular signal-regulated kinase MMP-2: Matrix metalloproteinases-2 MMP-9: Matrix metalloproteinases-9 NLRP3: NOD-like receptor protein 3 AGEs: Advanced glycation end products CSA: Cross-sectional area CM: Chronic migraine TNC: Trigeminal nucleus caudalis CGRP: Calcitonin gene-related peptide ICP: Intracranial pressure CSF: Cerebrospinal fluid IIH: Idiopathic intracranial hypertension References Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy